World journal of urology · 2026
Patterns of adjuvant intracavitary instillation and recurrence after endoscopic management of upper tract urothelial carcinoma.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Korn Philipp, Pallauf Maximilian, Herrera-Caceres Jaime O, Lokeshwar Soum, Essien Mark, Small Alexander, Raskolnikov Dima, Kleinmann Nir, Shvero Asaf, Matin Surena F, Labbate Craig, Kaimakliotis Hristos, Tachibana Isamu, Linehan Jennifer, Choe Jane, Shah Ojas, Movassaghi Miyad, Huang William, Persily Jesse, Perecman Aaron, Canes David, Pessoa Rodrigo R, Potretzke Aaron, Raman Jay D, Singla Nirmish
Аннотация
MAIN PURPOSE: Endoscopic management offers acceptable oncologic control in select patients with upper tract urothelial carcinoma (UTUC) while preserving renal function. Adjuvant intracavitary treatment with chemotherapy or Bacillus Calmette-Guérin (BCG) has been proposed to reduce recurrence risk. We aimed to evaluate the impact of adjuvant intracavitary treatment on ipsilateral UTUC recurrence following endoscopic management.
MATERIALS AND METHODS: We queried a multi-institutional cohort of patients who underwent endoscopic management for UTUC. Treatment groups were defined as no instillation, single post-operative instillation, or multiple instillations. Ipsilateral UTUC recurrence-free survival (RFS) was estimated using Kaplan-Meier curves and Cox proportional hazards models evaluated factors associated with recurrence.
RESULTS: A total of 599 renal units, of which 43 received single instillation and 86 multiple instillations, in 334 patients treated endoscopically for UTUC were analyzed. The median follow-up time for patients without recurrence was 12 months (IQR 4-33). Multiple adjuvant instillations of any intracavitary treatment were associated with a significantly improved RFS (HR 0.52, 95% CI 0.34-0.79), whereas a single instillation was not associated with a significant reduction in recurrence (HR 0.64, 95% CI 0.37-1.13). This association between multiple instillations and improved RFS remained significant after adjustment for clinical risk factors, including tumor grade (adjusted HR 0.36, 95% CI 0.16-0.81), and was confirmed in sensitivity analyses limited to patients with primary UTUC (HR 0.46, 95% CI 0.26-0.85).
CONCLUSION: Multiple intracavitary instillations of BCG or chemotherapy after endoscopic management of UTUC were associated with longer ipsilateral RFS. These findings suggest a potential benefit of repeated instillations and warrant prospective validation.
MATERIALS AND METHODS: We queried a multi-institutional cohort of patients who underwent endoscopic management for UTUC. Treatment groups were defined as no instillation, single post-operative instillation, or multiple instillations. Ipsilateral UTUC recurrence-free survival (RFS) was estimated using Kaplan-Meier curves and Cox proportional hazards models evaluated factors associated with recurrence.
RESULTS: A total of 599 renal units, of which 43 received single instillation and 86 multiple instillations, in 334 patients treated endoscopically for UTUC were analyzed. The median follow-up time for patients without recurrence was 12 months (IQR 4-33). Multiple adjuvant instillations of any intracavitary treatment were associated with a significantly improved RFS (HR 0.52, 95% CI 0.34-0.79), whereas a single instillation was not associated with a significant reduction in recurrence (HR 0.64, 95% CI 0.37-1.13). This association between multiple instillations and improved RFS remained significant after adjustment for clinical risk factors, including tumor grade (adjusted HR 0.36, 95% CI 0.16-0.81), and was confirmed in sensitivity analyses limited to patients with primary UTUC (HR 0.46, 95% CI 0.26-0.85).
CONCLUSION: Multiple intracavitary instillations of BCG or chemotherapy after endoscopic management of UTUC were associated with longer ipsilateral RFS. These findings suggest a potential benefit of repeated instillations and warrant prospective validation.